

---

# Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
<b>2</b>	<b>Clinical Studies</b>	<b>7</b>
<b>2.1</b>	<b>Dementia and Memory Disorders</b>	<b>7</b>
2.1.1	Clinical and Research Issues	7
2.1.2	Alzheimer's Disease and Mild Cognitive Impairment	9
2.1.2.1	Cerebral Glucose Metabolism	9
2.1.2.2	Cholinergic Degeneration	20
2.1.2.3	Other Receptors and Transmitters	22
2.1.2.4	Amyloid Imaging	22
2.1.2.5	Activation Studies	23
2.1.3	Dementia with Lewy Bodies	24
2.1.4	Frontotemporal Dementia and Related Disorders	25
2.1.5	Vascular Dementia	28
2.1.6	Creutzfeldt-Jakob Disease	30
2.1.7	Other Memory Disorders	31
2.1.7.1	Hypoxic and Global Ischemic Brain Damage	31
2.1.7.2	Other Amnesic Syndromes	31
<b>2.2</b>	<b>Movement Disorders</b>	<b>32</b>
2.2.1	Idiopathic Parkinson Disease	35
2.2.1.1	Diagnostic Issues	35
2.2.1.2	Dopamine Synthesis	37
2.2.1.3	Dopamine Release and Turnover	39
2.2.1.4	Dopamine Transporters	39
2.2.1.5	Vesicular Monoamine Transporter	40
2.2.1.6	Dopamine Receptors	40
2.2.1.7	Mesocortical Dopaminergic Innervation	41
2.2.1.8	Other Transmitters	41
2.2.1.9	Resting Glucose Metabolism	41
2.2.1.10	Activation Studies	42
2.2.1.11	Familial PD	42
2.2.1.12	Disease Progression	44
2.2.1.13	Depression in PD	45
2.2.1.14	Improving and Understanding Treatment Effects	45

2.2.2	Multiple System Atrophy . . . . .	48
2.2.2.1	Olivo-ponto-cerebellar Atrophy . . . . .	49
2.2.2.2	Striatonigral Degeneration . . . . .	50
2.2.2.3	Shy-Drager Syndrome . . . . .	50
2.2.3	Other Neurodegenerative Disorders . . . . .	52
2.2.3.1	Progressive Supranuclear Palsy . . . . .	52
2.2.3.2	Corticobasal Degeneration . . . . .	53
2.2.3.3	Disorders with Abnormal Deposition of Metals . . . . .	55
2.2.3.4	Parkinsonism Attributable to Toxic and Inflammatory Brain Damage . . . . .	55
2.2.3.5	Amyotrophic Lateral Sclerosis . . . . .	56
2.2.3.6	Other Rare Disorders . . . . .	56
2.2.4	Hyperkinetic Syndromes . . . . .	56
2.2.4.1	Huntington's Chorea (Huntington Disease) . . . . .	56
2.2.4.2	Other Choreic Disorders . . . . .	58
2.2.4.3	Restless Legs Syndrome . . . . .	58
2.2.4.4	Essential and Orthostatic Tremor . . . . .	59
2.2.4.5	Tourette Syndrome . . . . .	59
2.2.5	Dystonia and Related Disorders . . . . .	60
2.2.5.1	Idiopathic Dystonia and Torticollis . . . . .	60
2.2.5.2	DOPA-responsive Dystonia . . . . .	61
2.2.5.3	Dystonia Attributable to Localized Lesions or Degeneration . . . . .	61
2.2.6	Ataxia . . . . .	61
2.2.6.1	Spinocerebellar Ataxia . . . . .	62
2.2.6.2	Friedreich's Ataxia . . . . .	63
2.2.6.3	Other Ataxias . . . . .	63
2.3	<b>Brain Tumors . . . . .</b>	63
2.3.1	Biological Grading . . . . .	64
2.3.1.1	Glucose Consumption . . . . .	64
2.3.1.2	Amino Acid Uptake . . . . .	68
2.3.1.3	Nucleoside Uptake . . . . .	71
2.3.2	PET-Guided Stereotactic Biopsy . . . . .	71
2.3.3	Differentiation Between Recurrent Tumor and Radiation Necrosis . . . . .	71
2.3.4	Monitoring of Therapy . . . . .	73
2.3.5	Identification of Hypoxic Tumor Tissue . . . . .	77
2.3.6	Improving and Planning Therapy . . . . .	77
2.3.7	New Therapies . . . . .	79
2.3.8	Other Tracers for Brain Tumors . . . . .	80
2.3.9	Extracranial Tumors of the Nervous System . . . . .	80
2.3.10	Detection of Primary Tumors . . . . .	81
2.3.11	Activation Studies . . . . .	81
2.3.11.1	Motor Function . . . . .	82
2.3.11.2	Language . . . . .	84

<b>2.4</b>	<b>Cerebrovascular Disease</b>	86
2.4.1	Ischemic Stroke	87
2.4.2	Intracerebral and Subdural Hemorrhage	89
2.4.3	Subarachnoid Hemorrhage	90
2.4.4	Remote Effects (Diaschisis)	90
2.4.5	Chronic Hemodynamic Impairment	93
2.4.6	Moyamoya Disease	95
2.4.7	Genetic Disorders (MELAS, CADASIL)	95
2.4.8	Brain Function and Recovery After Stroke	95
2.4.8.1	Aphasia	96
2.4.8.2	Motor Function	98
2.4.8.3	Neglect	99
<b>2.5</b>	<b>Epilepsy</b>	100
2.5.1	Localization of Epileptogenic Foci	101
2.5.1.1	Temporal Lobe Epilepsy	101
2.5.1.2	Neocortical Focal Epilepsy	105
2.5.1.3	Ictal Studies	105
2.5.1.4	GABA-A and Benzodiazepine Receptors	106
2.5.1.5	Other Transmitters and Receptors	107
2.5.1.6	Inflammatory Lesions and Glial Reaction	108
2.5.2	Progression of Epileptic Lesions	109
2.5.3	Prediction of Surgical Outcome	109
2.5.4	Malformations of Cortical Development	109
2.5.5	Childhood Epileptic Syndromes	111
2.5.6	Language Dominance	112
2.5.7	Effects of Surgical Intervention and Medical Treatment	112
2.5.8	Generalized Epilepsy	113
<b>2.6</b>	<b>Other Neurological Disorders</b>	113
2.6.1	Traumatic Brain Injury	113
2.6.2	Persistent Vegetative State	114
2.6.3	Perinatal Brain Damage	115
2.6.4	Inflammatory Disease	117
2.6.5	Pain	119
2.6.6	Migraine and Cluster Headache	121
2.6.7	Narcolepsy	122
2.6.8	Hypoparathyroidism (Fahr's Disease)	122
2.6.9	Systemic Inherited Metabolic Disorders	122
<b>2.7</b>	<b>Psychiatric Disorders</b>	123
2.7.1	Depression	124
2.7.1.1	Cerebral Blood Flow and Cerebral Metabolic Rate (Glucose)	125
2.7.1.2	Serotonin Receptors	127
2.7.1.3	Serotonin Transporters	128
2.7.1.4	Other Transmitter Systems	128
2.7.2	Fatigue	128

2.7.3	Schizophrenia . . . . .	129
2.7.3.1	CBF and Energy Metabolism . . . . .	129
2.7.3.2	Activation Studies . . . . .	129
2.7.3.3	Dopamine Receptors and Dopamine Release . . . . .	130
2.7.3.4	Other Receptors. . . . .	131
2.7.3.5	Receptor Binding of Antipsychotic Drugs . . . . .	131
2.7.4	Anxiety Disorders . . . . .	131
2.7.4.1	Panic Disorder . . . . .	132
2.7.4.2	Phobic Disorders . . . . .	132
2.7.4.3	Obsessive-compulsive Disorder . . . . .	133
2.7.4.4	Posttraumatic Stress Disorder. . . . .	134
2.7.5	Drug and Substance Abuse . . . . .	135
2.7.5.1	Alcoholism . . . . .	135
2.7.5.2	Cocaine . . . . .	136
2.7.5.3	Amphetamine and Derivatives . . . . .	138
2.7.5.4	Opiates. . . . .	139
2.7.5.5	Nicotine . . . . .	140
2.7.5.6	Hallucinogens . . . . .	140
2.7.5.7	Phencyclidine . . . . .	140
2.7.6	Personality and Behavioral Disorders . . . . .	141
2.7.6.1	Borderline Personality Disorder . . . . .	141
2.7.6.2	Violence and Suicide . . . . .	141
2.7.7	Anorexia Nervosa and Bulimia . . . . .	142
<b>3</b>	<b>Imaging Brain Function . . . . .</b>	<b>143</b>
<b>3.1</b>	<b>Blood–Brain Barrier Transfer . . . . .</b>	<b>143</b>
<b>3.2</b>	<b>Cerebral Blood Flow . . . . .</b>	<b>147</b>
<b>3.3</b>	<b>Oxygen Consumption . . . . .</b>	<b>149</b>
<b>3.4</b>	<b>Glucose Consumption . . . . .</b>	<b>150</b>
<b>3.5</b>	<b>Influence of Brain Function on CBF and Metabolism . . . . .</b>	<b>152</b>
3.5.1	Wakefulness and Sleep . . . . .	153
3.5.2	Effect of Drugs . . . . .	153
3.5.3	The “Resting State”. . . . .	154
3.5.4	Activation Studies . . . . .	155
<b>3.6</b>	<b>Tissue Oxygen Pressure and pH. . . . .</b>	<b>156</b>
<b>3.7</b>	<b>Amino Acid Transport and Protein Synthesis . . . . .</b>	<b>156</b>
3.7.1	Transport-only Tracers . . . . .	157
3.7.2	Tracers with Incorporation into Proteins . . . . .	158
3.7.3	Precursors and Analogues for Transmitter Systems. . . . .	160
<b>3.8</b>	<b>Nucleosides and DNA Synthesis . . . . .</b>	<b>160</b>
<b>3.9</b>	<b>Molecular Imaging . . . . .</b>	<b>161</b>
3.9.1	Herpes Simplex Virus Thymidine Kinase Imaging . . . . .	163

3.9.2	Reporter Gene Imaging . . . . .	164
3.9.3	Oligonucleotides . . . . .	164
3.9.4	Apoptosis and p53 . . . . .	164
3.9.5	Cell Trafficking . . . . .	164
3.9.6	Angiogenesis . . . . .	165
<b>3.10</b>	<b>Dopamine System . . . . .</b>	<b>165</b>
3.10.1	Precursors and Analogues of Dopamine . . . . .	165
3.10.2	Dopamine Transporter . . . . .	167
3.10.3	Vesicular Monoamine Transporter . . . . .	168
3.10.4	D1 Receptors . . . . .	169
3.10.5	D2 Receptors . . . . .	169
3.10.6	Studies of Synaptic Dopamine Release . . . . .	170
3.10.7	Monoamine Oxidase . . . . .	172
<b>3.11</b>	<b>Cholinergic System. . . . .</b>	<b>173</b>
3.11.1	Acetylcholine Synthesis . . . . .	173
3.11.2	Vesicular Acetylcholine Transporter . . . . .	173
3.11.3	Nicotinic Receptors . . . . .	173
3.11.4	Muscarinic Receptors . . . . .	174
3.11.5	Acetylcholine Esterase . . . . .	174
<b>3.12</b>	<b>Serotonin System. . . . .</b>	<b>176</b>
3.12.1	Serotonin Precursors. . . . .	176
3.12.2	Serotonin Transporter . . . . .	177
3.12.3	Serotonin Receptors . . . . .	177
	3.12.3.1 Serotonin 1A Receptors . . . . .	177
	3.12.3.2 Serotonin 2A Receptors . . . . .	180
<b>3.13</b>	<b>Gamma-aminobutyric acid (GABA) . . . . .</b>	<b>180</b>
3.13.1	Central Benzodiazepine-binding Sites . . . . .	181
3.13.2	Peripheral Benzodiazepine Receptors . . . . .	181
<b>3.14</b>	<b>Glutamate and NMDA Receptors . . . . .</b>	<b>182</b>
<b>3.15</b>	<b>Adenosine Receptors . . . . .</b>	<b>182</b>
<b>3.16</b>	<b>Histamine Receptors . . . . .</b>	<b>182</b>
<b>3.17</b>	<b>Cannabinoid Receptors . . . . .</b>	<b>183</b>
<b>3.18</b>	<b>Opioid Receptors and Sigma Receptor . . . . .</b>	<b>183</b>
<b>3.19</b>	<b>Steroid Receptors . . . . .</b>	<b>184</b>
<b>3.20</b>	<b>Substance P. . . . .</b>	<b>184</b>
<b>3.21</b>	<b>Secondary Neurotransmitters. . . . .</b>	<b>185</b>
<b>4</b>	<b>Data Acquisition, Reconstruction, Modeling, Statistics . . . . .</b>	<b>187</b>
<b>4.1</b>	<b>Positron Emitters and Tracers . . . . .</b>	<b>187</b>
<b>4.2</b>	<b>Scanners and Detector Systems . . . . .</b>	<b>189</b>
<b>4.3</b>	<b>Data Acquisition . . . . .</b>	<b>191</b>
<b>4.4</b>	<b>Image Reconstruction . . . . .</b>	<b>192</b>

---

<b>4.5</b>	<b>Motion Detection and Correction . . . . .</b>	<b>194</b>
<b>4.6</b>	<b>Data Visualization . . . . .</b>	<b>194</b>
<b>4.7</b>	<b>Image Coregistration. . . . .</b>	<b>195</b>
4.7.1	Fiducial Markers . . . . .	196
4.7.2	Matching of Brain Structures . . . . .	197
4.7.3	Algorithms for Maximization of Similarity . . . . .	198
4.7.4	PET/CT and PET/MRI Scanners . . . . .	199
<b>4.8</b>	<b>Anatomical Standardization. . . . .</b>	<b>200</b>
4.8.1	Orientation of Transaxial Slices . . . . .	200
4.8.2	Matching of Individual Brains to Image Templates ("Spatial Normalization") . . . . .	201
4.8.3	Atlases for Identification of Anatomical Structures . . . . .	202
<b>4.9</b>	<b>Physiological Modeling . . . . .</b>	<b>203</b>
4.9.1	Blood and Homogeneous Tissue (One Tissue Compartment) . . . . .	205
4.9.1.1	Transport across the BBB . . . . .	206
4.9.1.2	Cerebral Blood Flow . . . . .	207
4.9.1.3	Mixed Effects of Transport and Blood Flow . . . . .	211
4.9.1.4	Measurement of the Partition Coefficient . . . . .	211
4.9.1.5	Saturable Transport and Enzyme Reactions . . . . .	212
4.9.2	Metabolism . . . . .	212
4.9.2.1	Irreversible Metabolism (Metabolic Trapping). . . . .	213
4.9.2.2	Measurement of Local Cerebral Glucose Metabolism . . . . .	214
4.9.2.3	The Reference Tissue Model for Dopamine Synthesis and Storage . . . . .	216
4.9.2.4	Reversible Metabolism or Binding . . . . .	217
4.9.3	Receptor Binding. . . . .	218
4.9.3.1	Irreversible Receptor Binding . . . . .	219
4.9.3.2	Equilibrium Approaches for Quantification of Reversible Receptor Binding . . . . .	220
4.9.4	Extraction of Model Parameters from Kinetic Data . . . . .	222
<b>4.10</b>	<b>Quantitative Data Analysis . . . . .</b>	<b>223</b>
4.10.1	Regions/Volumes of Interest . . . . .	225
4.10.2	Partial Volume Correction . . . . .	226
4.10.3	Statistical Models for Quantitative Data . . . . .	227
4.10.4	Parametric Imaging . . . . .	231
4.10.5	Statistical Parametric Mapping . . . . .	232
4.10.6	Lesion Detection and Pattern Recognition . . . . .	233
	<b>References . . . . .</b>	<b>235</b>
	<b>Subject Index . . . . .</b>	<b>285</b>

NeuroPET

Positron Emission Tomography in Neuroscience and  
Clinical Neurology

Herholz, K.; Herscovitch, P.; Heiss, W.-D.

2004, XV, 297 p. With CD-ROM., Hardcover

ISBN: 978-3-540-00691-6